TME Pharma N.V.
TME Pharma N.V., a clinical-stage biopharmaceutical company, focuses on the development of proprietary therapeutics for the treatment of cancer in Germany. The company's Spiegelmer platform has a proprietary pipeline of clinical-stage product candidates, including its lead cancer drug candidate, NOX-A12, which is under development as a combination therapy for various cancer indications, such as m… Read more
TME Pharma N.V. (ALTME) - Total Assets
Latest total assets as of June 2025: €2.29 Million EUR
Based on the latest financial reports, TME Pharma N.V. (ALTME) holds total assets worth €2.29 Million EUR as of June 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
TME Pharma N.V. - Total Assets Trend (2014–2024)
This chart illustrates how TME Pharma N.V.’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
TME Pharma N.V. - Asset Composition Analysis
Current Asset Composition (December 2024)
TME Pharma N.V.'s total assets of €2.29 Million consist of 98.7% current assets and 1.3% non-current assets.
| Asset Category | Amount (EUR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €3.24 Million | 95.1% |
| Accounts Receivable | €26.00K | 0.8% |
| Inventory | €0.00 | 0.0% |
| Property, Plant & Equipment | €34.00K | 1.0% |
| Intangible Assets | €4.00K | 0.1% |
| Goodwill | €0.00 | 0.0% |
Asset Composition Trend (2014–2024)
This chart illustrates how TME Pharma N.V.'s asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: TME Pharma N.V.'s current assets represent 98.7% of total assets in 2024, an increase from 66.9% in 2014.
- Cash Position: Cash and equivalents constituted 95.1% of total assets in 2024, up from 49.4% in 2014.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, a decrease from 2.0% in 2014.
- Asset Diversification: The largest asset category is cash and equivalents at 95.1% of total assets.
TME Pharma N.V. Competitors by Total Assets
Key competitors of TME Pharma N.V. based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
MedPacto Inc
KQ:235980
|
Korea | ₩51.58 Billion |
|
2H0
F:2H0
|
Germany | €15.27 Million |
|
Shenzhen CAU Technology Co Ltd
SHE:000004
|
China | CN¥260.55 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.58 Billion |
|
Nanhua Bio Medicine Co Ltd
SHE:000504
|
China | CN¥841.96 Million |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
|
China | CN¥509.14 Million |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
|
Hualan Biological EngineeringInc
SHE:002007
|
China | CN¥16.27 Billion |
TME Pharma N.V. - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - TME Pharma N.V. generates 0.01x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - TME Pharma N.V. is currently not profitable relative to its asset base.
TME Pharma N.V. - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.79 | 2.11 | 4.40 |
| Quick Ratio | 0.79 | 2.11 | 4.40 |
| Cash Ratio | 0.00 | 1.97 | 2.51 |
| Working Capital | €-588.00K | € 1.52 Million | € 8.35 Million |
TME Pharma N.V. - Advanced Valuation Insights
This section examines the relationship between TME Pharma N.V.'s asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 6.15 |
| Latest Market Cap to Assets Ratio | 0.04 |
| Asset Growth Rate (YoY) | 36.7% |
| Total Assets | €3.41 Million |
| Market Capitalization | $137.38K USD |
Valuation Analysis
Below Book Valuation: The market values TME Pharma N.V.'s assets below their book value (0.04 x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: TME Pharma N.V.'s assets grew by 36.7% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for TME Pharma N.V. (2014–2024)
The table below shows the annual total assets of TME Pharma N.V. from 2014 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | €3.41 Million | +36.73% |
| 2023-12-31 | €2.49 Million | -52.47% |
| 2022-12-31 | €5.24 Million | -46.35% |
| 2021-12-31 | €9.77 Million | -8.32% |
| 2020-12-31 | €10.65 Million | +515.13% |
| 2019-12-31 | €1.73 Million | -61.66% |
| 2018-12-31 | €4.52 Million | +386.33% |
| 2017-12-31 | €929.00K | -67.62% |
| 2016-12-31 | €2.87 Million | -52.51% |
| 2015-12-31 | €6.04 Million | +95.50% |
| 2014-12-31 | €3.09 Million | -- |